Gefor 80mg/500mg Tablet is a combination oral hypoglycemic agent containing Gliclazide 80mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The synergistic action of these agents helps achieve better blood glucose regulation in patients inadequately controlled by diet, exercise, and monotherapy. Gefor is typically prescribed when monotherapy with either agent is insufficient to maintain optimal glycemic levels. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia, particularly due to Gliclazide. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or risk factors for lactic acidosis. Gefor should be used under medical supervision with appropriate lifestyle modifications to optimize diabetes management and reduce the risk of long-term complications.